Fostamatinib and the risk of acute aortic dissection in immune thrombocytopenia
British Journal of Clinical Pharmacology · 2025
DOI: 10.1002/bcp.70289 ↗Kurz gefasst
Fallbericht in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Paul Dalmas und 7 weiteren Autor:innen. Beteiligte Einrichtung: Aix Marseille University, APHM, Internal Medicine Department, La Timone Hospital, Marseille, France. Hauptthemen laut MEDLINE: Aortic Dissection, Oxazines, Purpura, Thrombocytopenic, Idiopathic, Pyridines. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Immune thrombocytopenia (ITP) is a rare autoimmune disorder characterized by platelet destruction. While most patients respond to first‐ or second‐line therapies, a small subset is multirefractory. Fostamatinib , an oral spleen tyrosine kinase ( SYK ) inhibitor, is a therapeutic option in these cases. We report a case of an acute aortic dissection (AAD) occurring in a patient without traditional cardiovascular risk factors, 3 months after fostamatinib initiation. A 70‐year‐old woman with a 30‐year history of ITP, unresponsive to multiple therapies, was treated with fostamatinib and achieved a complete haematologic response. She presented with sudden chest pain and was diagnosed with Stanford A (DeBakey type 1) AAD requiring emergency surgery. Histological analysis of her aortic tissue showed a 25% reduction in phosphorylated SYK expression compared to a control sample, without alteration in smooth muscle cell markers. The absence of predisposing conditions (hypertension, smoking, genetic disorders) led us to explore a potential link between fostamatinib and AAD. Experimental data suggest that SYK inhibition exacerbates aortic wall vulnerability, and off‐target effects of fostamatinib on VEGF receptors may further weaken vascular integrity. This case highlights a possible association between fostamatinib and AAD, potentially mediated by SYK and VEGFR inhibition. While causality cannot be definitively established, clinicians should be vigilant when prescribing fostamatinib, even in patients without known risk factors for AAD. Further studies are needed to clarify the vascular safety profile of fostamatinib in ITP and other settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Aix Marseille University, APHM, Internal Medicine Department, La Timone Hospital, Marseille, France.
- Department of cardiac Surgery, La Timone Hospital, Marseille, France.
- Aix-Marseille University, INSERM, MMG U1251, Marseille, France.
- Radiology Department, La Timone Hospital, Assistance Publique Des Hôpitaux de Marseille, Marseille 05, France.
- Aix Marseille University, APHM, Pharmacologie Clinique & Pharmacosurveillance Department, Sainte Marguerite Hospital and Regional Pharmacovigilance Center, Marseille, France.
ORCID-Profile: Paul Dalmas, Joelle Micallef
Zitieren
APA
Dalmas, P., Theron, A., Badaoui, R., Zaffran, S., Mchinda, R., Micallef, J., Schleinitz, N., & Ebbo, M. (2025). Fostamatinib and the risk of acute aortic dissection in immune thrombocytopenia. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70289
Vancouver
Dalmas P, Theron A, Badaoui R, Zaffran S, Mchinda R, Micallef J, et al. Fostamatinib and the risk of acute aortic dissection in immune thrombocytopenia. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70289
BibTeX
@article{Dalmas2025,
author = {Dalmas, Paul and Theron, Alexis and Badaoui, Rita and Zaffran, Stéphane and Mchinda, Rayid and Micallef, Joelle and Schleinitz, Nicolas and Ebbo, Mikael},
title = {Fostamatinib and the risk of acute aortic dissection in immune thrombocytopenia},
journal = {British Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1002/bcp.70289}
}
EUVIMED